UPB Stock Analysis: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$7.28
-0.25 (-3.32%)
▼
5d:
-1.62%
30d:
+15.92%
90d:
-30.6%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: UPB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: UPB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $7.28, which is considered slightly high relative to its 30-day fair value range of $6.18 to $7.41.
Technical Outlook: Technically, UPB is in a downtrend. Immediate support is located at $6.56, while resistance sits at $8.00. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: UPB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $38.25 (+425.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, UPB is in a downtrend. Immediate support is located at $6.56, while resistance sits at $8.00. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: UPB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $38.25 (+425.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.18 -
$7.41
Company Quality Score
60/100
(HOLD)
Options IV Signal
67th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
72.9%
All Signals
- NEUTRAL: Options fairly priced (IV 67th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 425.4% below Wall St target ($38.25)
Trading Range Analysis
30-Day Trading Range
$6.18 -
$7.41
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.35
(18.6%)
Support & Resistance Levels
Support Level
$6.56
Resistance Level
$8.00
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.52
Wall Street Target
$38.25
(+425.4%)
Revenue Growth (YoY)
82.7%
Share & Embed Analysis
Last updated: July 14, 2026 5:55 AM ET
Data refreshes hourly during market hours. Next update: 6:55 AM
Data refreshes hourly during market hours. Next update: 6:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Gray
SELL
852 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$99 | 44 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
